Trial Profile
Patient-Reported Outcomes In Rheumatoid Arthritis Patients Treated With Tofacitinib Or Biological Disease-Modifying Antirheumatic Drugs (DMARDS) In Real Life Conditions
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 03 Jun 2021
Price :
$35
*
At a glance
- Drugs Tofacitinib (Primary) ; Antirheumatics; Disease-modifying antirheumatics; Etanercept; Infliximab; Rituximab; Tocilizumab
- Indications Rheumatoid arthritis
- Focus Therapeutic Use
- Sponsors Pfizer
- 20 May 2021 Results assessing impact of access limitations on patient centered outcomes in Latin-American patients with Rheumatoid arthritis presented at the 26th Annual International Meeting of the International Society for Pharmacoeconomics and Outcomes Research
- 20 May 2021 Primary endpoint (Change From Baseline in Routine Assessment of Patient Index Data 3 (RAPID3) Score at Month 6) , has not been met according to Results presented at the 26th Annual International Meeting of the International Society for Pharmacoeconomics and Outcomes Research
- 20 May 2021 Results presented at the 26th Annual International Meeting of the International Society for Pharmacoeconomics and Outcomes Research